Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy-Reference-Cited by-同舟云学术

Histoplasmosis in an off-trail Hiker receiving ustekinumab: Implications for Preventive and diagnostic strategies for patients receiving anti-IL-12/23 therapy

Published:2021-06 Issue: Volume:32 Page:43-46
ISSN:2211-7539
Container-title:Medical Mycology Case Reports
language:en
Short-container-title:Medical Mycology Case Reports

Author:

Huang Yun-Han^ORCID,Magleby Reed^ORCID,Rao Rema^ORCID,Walsh Thomas J.,Singh Harjot K.

Funder

National Cancer Institute

National Institute of General Medical Sciences

National Institutes of Health

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology

Reference18 articles.

1. Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for crohn's disease. N. Engl. J. Med.. 1997. Oct. 9;337(15):1029–1036.

2. Sandborn WJ, Gasink C, Gao L-L, Blank MA, Johanns J, Guzzo C, et al Ustekinumab induction and maintenance therapy in refractory crohn's disease. N. Engl. J. Med.. 2012. Oct. 18;367(16):1519–1528.

3. Comparative risk of serious infections with biologic and/or immunosuppressive therapy in patients with inflammatory bowel diseases: a systematic review and meta-analysis;Singh;Clin. Gastroenterol. Hepatol.,2020

4. Ustekinumab safety in psoriasis, psoriatic arthritis, and crohn's disease: an integrated analysis of phase II/III clinical development programs;Ghosh;Drug Saf.,2019

5. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, et al IM-UNITI: three-year efficacy, safety, and immunogenicity of ustekinumab treatment of crohn's disease. J Crohns Colitis. 2020. Jan. 1;14(1):23–32.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isolated gastrointestinal histoplasmosis with a negative urine antigen test mimicking ulcerative colitis flare: a case report;Gastroenterology Report;2023-12-22

2. Multiple drugs;Reactions Weekly;2021-04